Skip to content

Vaxcyte, Inc. PCVX Total Operating Expenses

Total Operating Expenses at other companies

Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$62.67M+20.7%

Segments

By segment

See full
Reportable Segment$345.85M+91.3%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s total operating expenses?
Vaxcyte, Inc. (PCVX) reported total operating expenses of $345.85M in Q1 2026.
How has Vaxcyte, Inc.'s total operating expenses changed year-over-year?
Vaxcyte, Inc.'s total operating expenses increased by 91.3% year-over-year, from $180.79M to $345.85M.
What is the long-term trend for Vaxcyte, Inc.'s total operating expenses?
Over 4 years (2021 to 2025), Vaxcyte, Inc.'s total operating expenses has grown at a 72.8% compound annual growth rate (CAGR), from $103.67M to $923.68M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.